Horizon Discovery Group plc, the international life science company supplying genomics research tools and services that power genomic research and the development of personalized medicines, announces the launch of its new e-commerce platform and integrated webshop, and the expansion of its UK-based headquarters.
Horizon’s investment in an advanced e-commerce platform with integrated webshop, completed on time and on budget, alongside investments in an Enterprise Resource Planning (ERP) system, is in line with the company’s stated strategy to invest in operational infrastructure to drive core revenue growth.
These systems are designed to substantially increase the number of sales leads generated, connecting customers, in particular academic, with Horizon’s catalogue of more than 20,000 cell lines and in vivo models, and clinical labs with the company’s extensive collection of reference standards. Further, by linking related products and services with business intelligence, the company will be able to optimize its understanding of customer needs.
In addition, Horizon is expanding its Cambridge, UK-based headquarters, changing registered office, and expects to be able to begin operating from the new building in the first half of 2016. The facility, at 8100 Cambridge Research Park and based next door to Horizon’s current headquarters, will accommodate up to 200 staff across manufacturing, services, research and general and administrative functions, and provides the company a global footprint of 100,000 square feet in the UK, US and Austria.
Commenting on the announcement, Dr Darrin M. Disley, Horizon’s Chief Executive Officer, said: “The launch of our e-commerce platform, webshop and ERP is an important milestone for the company and will underpin the greater scale up of our business for continued strong revenue growth. The expansion of our headquarters also reaffirms our commitment to the Cambridge, UK biotechnology community, and follows the continued growth in our products, services, and leveraged R&D businesses as described recently in our interim results.”